on Sandoz Group AG (isin : CH1243598427)
Sandoz Launches Enzeevu in US to Expand Retinal Treatment Options
Sandoz Group AG has announced the US launch of Enzeevu, a biosimilar treatment for various retinal diseases, including neovascular age-related macular degeneration, diabetic retinopathy, and macular edema. Approved by the FDA in August 2024, Enzeevu provides an affordable option for over 30 million Americans affected by these conditions. The launch is part of Sandoz's strategy to enhance its biosimilar portfolio under its Bio100 ambition.
The introduction of Enzeevu, delivered via a pre-filled syringe, aims to improve patient access to retinal care, addressing treatment costs, a significant barrier. Enzeevu shows clinical equivalence to Eylea, the reference medicine, fulfilling all FDA biosimilarity criteria. It is interchangeable with the reference for all approved indications, supporting cost-effective healthcare.
Sandoz has also secured a multi-year private-label agreement to expand Enzeevu's reach in the US market, commencing mid-2027. This aligns with Sandoz’s history of successful private-label biosimilars. The agreement ensures committed volumes from the second half of 2027, strengthening Sandoz’s position in the ophthalmology sector.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Sandoz Group AG news